Clinical Genomics’ gene-based blood test Colvera a first

Home grown success story drives the commercialisation of Colvera™, a liquid biopsy test for colorectal cancer (CRC) recurrence, and the focus of growing clinical evidence to support its use as the first widely adopted blood test for screening for colorectal cancer.

Colvera - News

OneVentures played a key role in the financing by increasing their position in Clinical Genomics and enabling many of their limited partners to invest further.

OneVentures Managing Partner and Clinical Genomics Director Paul Kelly MD said, “The company is poised to achieve some very significant milestones over the next couple years that should further drive revenue and value growth.”

Learn More

Posted in — The Australian


You may also like

26 March 2018

OVO Mobile snaps up e-sports broadcast rights

11 February 2015

Investors keen on biotech injection: OneVentures

01 November 2013

Hatchtech gets new VC backing for lice treatment trial

01 June 2018

Clinical Genomics’ gene-based blood test Colvera a first

20 December 2014

Old world money unites with best and brightest in world of disruption

02 June 2021

Covid-19 vaccine could soon be needle-free

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor